Myopic Choroidal Neovascularisation: Eylea

Oral Answers to Questions — Health – in the House of Commons at 12:00 am on 10th October 2017.

Alert me about debates like this

Photo of Ian Austin Ian Austin Labour, Dudley North 12:00 am, 10th October 2017

What his policy is on making Eylea available as a treatment for myopic choroidal neovascularisation.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence is developing guidance on the use of Eylea for the treatment of myopic CNV. NICE has published draft guidance for appeal that recommends use of the drug subject to a patient access scheme that makes it available to the NHS at a discounted price. NICE expects to publish final guidance this November.

Photo of Ian Austin Ian Austin Labour, Dudley North

NICE needs to get a move on, because these drugs have been available to patients in Scotland and Wales, but patients in England will be going blind in the meantime.

Some people are told that their eyesight is too good to be treated, but by the time it has declined, they are told that nothing can be done to help. Will the Secretary of State meet my constituent, Elaine Shaw, who has been campaigning on the issue, the Macular Society and the Royal National Institute of Blind People so that we can discuss how to prevent people from facing an increased and unacceptable risk of preventable sight loss?

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

Obviously I would be deeply concerned if patients were losing their sight due to treatment not happening in a timely way. Dudley clinical commissioning group tells me that it has already made funding available for Eylea following consideration of the NICE evidence summary issued in June 2016. This is the first drug that we have appraised through the new fast-track process for treatments that demonstrate clear cost-effectiveness. Patients will have routine access to Eylea from 1 December should the guidance remain unchanged. Of course, I would be happy to meet the hon. Gentleman and his constituent.